Jazz Pharmaceuticals Announces FDA Acceptance and Priority Review of Supplemental Biologics License Application for Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2+ Locally Advanced or Metastatic GEA ...Middle East

Prescription Drug User Fee Act (PDUFA) date set for August 25, 2026 For U.S. media and investors only DUBLIN, April 27, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the U.S. Food and Drug Administration (FDA) accepted for filing with Priority Review...

Hence then, the article about jazz pharmaceuticals announces fda acceptance and priority review of supplemental biologics license application for ziihera zanidatamab hrii combinations in first line her2 locally advanced or metastatic gea was published today ( Monday 27/04/2026 - 02:49 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Jazz Pharmaceuticals Announces FDA Acceptance and Priority Review of Supplemental Biologics License Application for Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2+ Locally Advanced or Metastatic GEA )

Also on site :

• Führend in einer neuen Ära der Familienmobilität! CHERY TIGGO V, das 3-in-1-Familienfahrzeug, debütiert auf der AutoChina2026
• NYT ‘Connections’ Hints, Clues and Answers Monday, April 27, 2026
• King Charles US visit: What to know about the itinerary, Congress address